Sharp Daily
No Result
View All Result
Saturday, October 25, 2025
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team
Sharp Daily
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team
No Result
View All Result
Sharp Daily
No Result
View All Result
Home News

AstraZeneca donates ultrasound biopsy machine to boost prostate cancer detection in Kenya

Judd Mutua by Judd Mutua
November 3, 2023
in News
Reading Time: 2 mins read

AstraZeneca, has donated a state-of-the-art ultrasound biopsy machine to Kenyatta National Hospital.

“The introduction of this ultrasound biopsy machine represents a significant step forward in our ongoing efforts to enhance prostate cancer diagnosis. Early detection is crucial in improving treatment outcomes for patients. With this advanced equipment, we aim to reduce the number of late-stage diagnoses and provide more effective treatments to those under our care.” Stated Dr. Evanson Kamuri, CEO of Kenyatta National Hospital

Read more: British International Investment commits USD 26.5 million to AFEX to boost food security in Africa

Six other hospitals across Kenya will also receive ultrasound biopsy machines by the end of the year include Moi University Teaching & Referral Hospital (Eldoret), Kenyatta University Teaching, Referral & Research Hospital (Nairobi), Jaramogi Oginga Odinga Teaching & Referral Hospital (Kisumu), Coast General Teaching & Referral Hospital (Mombasa), Meru Teaching and Referral Hospital (Meru), and Kakamega County General Teaching and Referral Hospital (Kakamega).

RELATEDPOSTS

How public ratings could shift healthcare dynamics in Kenya

September 4, 2025

HealthCare investment trends and insights

June 19, 2025

In addition to the ultrasound biopsy machine, Kenyatta National Hospital will also receive 3-4 reusable biopsy guns and 10,000 specialist kits for diagnosing prostate cancer through a blood test.

The donation is part of a broader initiative aimed at equipping seven “centers of excellence” in hospitals across Kenya with cutting-edge diagnostic tools.

To do AstraZeneca has partnered with The National Cancer Institute of Kenya (NCI Kenya) and the Kenya Association of Urological Surgeons (KAUS) to improve access to early and accurate detection for prostate cancer patients in the country.

“Our partnership with the National Cancer Institute of Kenya and KAUS to address prostate cancer symbolizes our dedication to fighting the growing burden of cancer in Kenya. By improving equitable access to technology that enables early diagnosis, we aim to enhance patient outcomes and, in the process, transform cancer care on the continent,” Said Pelin Incesu, Area Vice President for the Middle East and Africa at AstraZeneca

The partnership aims to reduce the current scenario in Kenya which sees 80 percent of prostate cancer patients diagnosed with advanced disease stages and aggressive tumors.

The initiative was inaugurated at Kenyatta National Hospital and will serve as the cornerstone of AstraZeneca’s Cancer Care Africa program in Kenya.

Read more: Kenya to use NGAOs to advance the Bottom Up Transformation model

The program aims to enhance outcomes for individuals affected by cancer in Kenya and across the continent, regardless of their socio-economic or geographic background. With a focus on health equity through the adoption of cutting-edge health technologies, making cancer screening more accessible, even in remote and underserved communities.

As part of the partnership, NCI Kenya and KAUS will set the benchmark for prostate cancer practice and standards across counties, ensuring that each of the seven hospital centers improve in clinical care, research innovation, and capacity building.

Email your news TIPS to editor@thesharpdaily.com

Previous Post

Investing in long-term value creation in an evolving economic landscape

Next Post

Tackling human rights violations through investment strategies

Judd Mutua

Judd Mutua

Judd Mutua is a journalist with wide ranging interests ranging from the world of finance to the latest in tech and business news. Off duty you can find him reading his favorite books and manga. Send tips via jmutua@thesharpdaily.com

Related Posts

News

Start Q4 strong with the Cytonn Money Market Fund

October 9, 2025
News

Kenya Q2’ 2025 GDP growth accelerates to 5.0%

October 3, 2025
News

Argentina’s crisis and Kenya’s lessons on political economy and market confidence

September 25, 2025
News

Kenya’s financial system remains stable but faces rising risks

September 25, 2025
News

Where do Kenyan stock returns come from? A napkin framework

September 19, 2025
News

September snapshot: CMMF yields 13.12% as month unfolds

September 5, 2025

LATEST STORIES

Kenya tightens crypto regulations after INTERPOL flags terror-financing scheme

October 24, 2025

Sidian Bank reshapes leadership in strategic transition

October 24, 2025

IRA drafts new regulations to introduce virtual assets insurance in Kenya

October 24, 2025

Understanding Umbrella vs Occupational Retirement Benefits Schemes in Kenya

October 24, 2025

Sovereign Wealth & Infrastructure Funds in Focus

October 24, 2025

CBK turns to gold in bid to diversify reserves and boost stability

October 24, 2025

2024 cooperatives bill seeks to modernize governance and member protection

October 23, 2025

Coca-Cola HBC to acquire 75.0% of CCBA for USD 3.4bn by 2026

October 23, 2025
  • About Us
  • Meet The Team
  • Careers
  • Privacy Policy
  • Terms and Conditions
Email us: editor@thesharpdaily.com

Sharp Daily © 2024

No Result
View All Result
  • Home
  • News
    • Politics
  • Business
    • Banking
  • Investments
  • Technology
  • Startups
  • Real Estate
  • Features
  • Appointments
  • About Us
    • Meet The Team

Sharp Daily © 2024